{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:06:11Z","timestamp":1794881171955,"version":"4.9.1"},"reference-count":34,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the occurrence of chickenpox in children with cancer who received varicella immunoglobulin (VZIG) or aciclovir as postexposure prophylaxis (PEP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective multicentre service evaluation of children with cancer who received either VZIG or aciclovir as PEP following significant exposure to varicella zoster virus (VZV) over a 24-month period from May 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Data were collected from 9 UK Paediatric Oncology Primary Treatment Centres.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Children under 16 years old with a diagnosis of cancer and\/or previous haematopoietic stem cell transplant who were VZV seronegative at exposure and\/or diagnosis and received PEP following significant VZV exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>The primary outcome was the incidence of breakthrough varicella within 6 weeks of VZV exposure and treatment with PEP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 105 eligible patients were registered with a median age of 4.9 years (range 1.1\u201310.5\u2009years). Underlying diagnoses were acute leukaemia (64), solid tumours (22), Langerhans cell histiocytosis (9), central nervous system (CNS) tumours (8) and other (2). Aciclovir was received by 86 patients (81.9%), 18 received VZIG (17.1%) and 1 valaciclovir (0.9%). There were seven reported break-through VZV infections in 103 patients at follow-up (7\/103, 6.8%). Clinical VZV developed in 5\/84 of the aciclovir group (6.0%, 95%\u2009CI 2.0 to 13.3) and 2\/18 of VZIG group (11.1%, 95%\u2009CI 1.4 to 34.7). All breakthrough infections were either mild (5\/7) or moderate (2\/7) in severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Aciclovir is a safe and effective alternative to VZIG as VZV PEP in children with cancer and should be considered as standard of care.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2022-324396","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T17:21:15Z","timestamp":1657300875000},"page":"1029-1033","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["PEPtalk 3: oral aciclovir is equivalent to varicella zoster immunoglobulin as postexposure prophylaxis against chickenpox in children with cancer \u2013 results of a multicentre UK evaluation"],"prefix":"10.1136","volume":"107","author":[{"given":"Claire","family":"Cuerden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-7433","authenticated-orcid":false,"given":"Paul T","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Amirthalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-9497","authenticated-orcid":false,"given":"Jessica","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"2023093005400982000_107.11.1029.1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.123232"},{"key":"2023093005400982000_107.11.1029.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2445-2","article-title":"Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization","volume":"17","author":"Riera-Montes","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2023093005400982000_107.11.1029.3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4274\/tjh.2016.0046","article-title":"Varicella-Zoster virus infections in pediatric malignancy patients: a seven-year analysis","volume":"33","author":"D\u00fczg\u00f6l","year":"2016","journal-title":"Turk J Haematol"},{"key":"2023093005400982000_107.11.1029.4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1542\/peds.80.4.465","article-title":"Varicella in children with cancer: impact of antiviral therapy and prophylaxis","volume":"80","author":"Feldman","year":"1987","journal-title":"Pediatrics"},{"key":"2023093005400982000_107.11.1029.5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jiac.2016.07.005","article-title":"Varicella with rapidly progressive hepatitis presenting with multiple hepatic nodules in a child with acute leukemia","volume":"22","author":"Han","year":"2016","journal-title":"J Infect Chemother"},{"key":"2023093005400982000_107.11.1029.6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-0219"},{"key":"2023093005400982000_107.11.1029.7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/INF.0000000000000737","article-title":"Failure of a single varicella vaccination to protect children with cancer from life-threatening breakthrough varicella","volume":"34","author":"Kelley","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2023093005400982000_107.11.1029.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.595478","article-title":"Different clinical presentations and outcomes of disseminated varicella in children with primary and acquired immunodeficiencies","volume":"11","author":"Bastard","year":"2020","journal-title":"Front Immunol"},{"key":"2023093005400982000_107.11.1029.9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/08880018.2016.1245805","article-title":"Varicella in pediatric oncology patients in the post-vaccine era-Analysis of routine hospital data from Bavaria (Germany), 2005-2011","volume":"33","author":"Streng","year":"2016","journal-title":"Pediatr Hematol Oncol"},{"key":"2023093005400982000_107.11.1029.10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1542\/peds.56.3.388","article-title":"Varicella in children with cancer: seventy-seven cases","volume":"56","author":"Feldman","year":"1975","journal-title":"Pediatrics"},{"key":"2023093005400982000_107.11.1029.11","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.209650"},{"key":"2023093005400982000_107.11.1029.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.042"},{"key":"2023093005400982000_107.11.1029.13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/pbc.21521","article-title":"Chickenpox in varicella IgG positive patients: experience of a regional paediatric oncology centre","volume":"51","author":"Manley","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2023093005400982000_107.11.1029.14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/INF.0000000000001920","article-title":"Lessons from an outbreak of varicella infection in pediatric hemato-oncology patients","volume":"37","author":"Manistarski","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2023093005400982000_107.11.1029.15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/pbc.25086","article-title":"Varicella zoster immune status in children treated for acute leukemia","volume":"61","author":"Patel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2023093005400982000_107.11.1029.16","unstructured":"Public Health England . Guidance on issuing varicella zoster immunoglobulin (VZIG), 2017."},{"key":"2023093005400982000_107.11.1029.17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bulcan.2021.11.016","article-title":"Varicella post-exposure management for pediatric oncology patients","volume":"109","author":"Costa","year":"2022","journal-title":"Bull Cancer"},{"key":"2023093005400982000_107.11.1029.18","unstructured":"Prevention CfDCa. chickenpox (varicella), 2016. Available: https:\/\/www.cdc.gov\/chickenpox\/hcp\/clinical-overview.html"},{"key":"2023093005400982000_107.11.1029.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)95766-1"},{"key":"2023093005400982000_107.11.1029.20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/inf.1983.15.issue-4.02","article-title":"Zoster immunoglobulin in varicella prophylaxis. A study among high-risk patients","volume":"15","author":"Hanngren","year":"1983","journal-title":"Scand J Infect Dis"},{"key":"2023093005400982000_107.11.1029.21","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.4.737"},{"key":"2023093005400982000_107.11.1029.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80697-X"},{"key":"2023093005400982000_107.11.1029.23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MPH.0000000000001835","article-title":"Up to a quarter of children with cancer develop breakthrough clinical varicella despite receiving post-exposure prophylaxis with varicella immunoglobulin: a single center UK experience over 3 years","volume":"43","author":"Prince","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"2023093005400982000_107.11.1029.24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhin.2009.01.020","article-title":"Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir","volume":"72","author":"Shinjoh","year":"2009","journal-title":"J Hosp Infect"},{"key":"2023093005400982000_107.11.1029.25","unstructured":"Immunisation of the Immunocompromised Child . Best practice statement. Royal College of paediatrics and child health, 2002. Available: http:\/\/rcpch.adlibhosting.com\/files\/Immunisation%20of%20the%20Immunocomprom ised%20Child%C2%A02002-02"},{"key":"2023093005400982000_107.11.1029.26","doi-asserted-by":"crossref","first-page":"853.2","DOI":"10.1136\/archdischild-2012-302591","article-title":"Varicella postexposure prophylaxis in children with cancer: urgent need for a randomised controlled trial","volume":"97","author":"Bate","year":"2012","journal-title":"Arch Dis Child"},{"key":"2023093005400982000_107.11.1029.27","doi-asserted-by":"crossref","first-page":"759.2","DOI":"10.1136\/archdischild-2011-301496","article-title":"Postexposure chickenpox prophylaxis in children with leukaemia: a reply to the recent PEPtalk study and report of a service evaluation in a tertiary paediatric haematology centre in the UK","volume":"97","author":"Samuelson","year":"2012","journal-title":"Arch Dis Child"},{"key":"2023093005400982000_107.11.1029.28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/MPH.0000000000001125","article-title":"Successful prevention of varicella outbreak with oral aciclovir following Party for pediatric oncology patients","volume":"40","author":"Beckingham","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"2023093005400982000_107.11.1029.29","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-314212"},{"key":"2023093005400982000_107.11.1029.30","unstructured":"Public Health England . Updated guidelines on post exposure prophylaxis (PEP) for varicella\/shingles, 2019. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/812526\/PHE_PEP_VZIG_guidance_for_health_professionals.pdf"},{"key":"2023093005400982000_107.11.1029.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441302"},{"key":"2023093005400982000_107.11.1029.32","doi-asserted-by":"publisher","DOI":"10.1136\/adc.69.6.639"},{"key":"2023093005400982000_107.11.1029.33","unstructured":"Public Health England . Guidelines on post-exposure prophylaxis for varicella\/shingles, 2022. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1073013\/UKHSA_guidelines_on_VZ_post_exposure_prophylaxis.pdf [Accessed 03 Jun 2022]."},{"key":"2023093005400982000_107.11.1029.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-05656-6","article-title":"Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program","volume":"21","author":"Gans","year":"2021","journal-title":"BMC Infect Dis"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2022-324396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T12:42:32Z","timestamp":1696077752000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2022-324396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,19]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/archdischild-2022-324396"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2022-324396","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}